Mumbai: Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ended 30th June 2025.

Financial Highlights

  • Revenue increased by 10% to Rs.1,711 Cr.
  • EBITDA up by 20% to Rs. 288 Cr.
  • EBITDA Margin at 17% of Revenue
  • Profit Before Tax up by 21% to Rs.191 Cr.
  • Net Profit at Rs.154 Cr. up by 15%.

Commenting on the results, Mr. Pranav Amin MD, Alembic Pharmaceuticals Limited, said, we began FY26 on a strong note, delivering revenue growth across all businesses. The growth was driven by a 21% increase in RoW markets, reflecting our strategic expansion and disciplined execution across geographies. Despite ongoing pricing pressure, our US business grew by 13%, supported by volume gains. As we ramp up utilization of our new manufacturing facilities and continue to drive cost optimization initiatives, we expect to benefit from improved operating leverage.

Operational Highlights

India Branded Business

  • India Branded Business delivered a 5% YoY growth, reaching ₹599 Cr in revenue for the quarter.
  • Good momentum in Specialty Therapies with Gynaecology, Cardiology, Anti-Diabetic, Ophthalmology and Animal healthcare segments demonstrating healthy growth.
  • Anti-infective and Cough & Cold segments grew in line with represented market performance, with robust operational execution.
  • Successfully introduced 3 new products during the quarter.

International Business

  • US Generics grew by 13% to Rs. 523 Cr. for the quarter.
  • 4 Launches in the US market during the quarter.
  • Ex-US International Generics grew by 21% to Rs. 328 Cr. for the quarter.
  • 6 ANDA approvals received during the quarter, 223 Cumulative ANDA approvals.

API Business

  • API business grew by 1% to Rs. 261 Cr. for the quarter.

The summary of Total Revenue is as under:  

 (Rs in Cr.)

ParticularsQ1 FY26Q1 FY25% Change
Formulation   
  India                            5995725%
  USA   Ex- US523 328461 27113% 21%
API2612591%
Total1,7111,56210%